The global Next-Generation Sequencing (NGS) Sample Preparation Market size is expected to reach USD 5.80 billion by 2025, expanding at a CAGR of 11.19% over the forecast period according to a new report by Grand View Research, Inc. Development of companion diagnostics and personalized medicine is expected to enhance the adoption of next-generation sequencing protocols in clinical practice. NGS technology is widely applicable in theranostics domain thus leading to growth in NGS sample preparation market.
In
addition, an increase in sequencing capacity and speed has led to a rise in
demand for high-throughput NGS sample handling solutions. Therefore, key
players are focused on the development of automated platforms for sample
preparation for next-generation sequencing.
For
instance, the Bravo NGS manufactured by Agilent Technologies, Inc. efficiently
automates library preparation for NGS implementation and reduces the overall
time of the process. A laboratory technician can use Bravo NGS to prepare whole
genome libraries for nearly 1,000 samples every week. The system also reduces
variability by nearly 39% as compared to other manual methods.
Request
a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/next-generation-sequencing-sample-preparation-market
Further Key Findings from the Report Suggest:
- Semi-automated
library preparation segment dominated the workflow segment in 2018 and is
projected to remain on the top in terms of revenue generation in the
coming years
- Combination
of automated and manual approaches for library preparation is attributed
to the highest share of the segment
- Market
entities are engaged in strategic partnerships to develop library
preparation protocols on semi-automated technologies
- For
instance, Illumina partnered with Hamilton Company for developing
automated and semi-automated library preparation platform. The automation
of preliminary steps aid in the reduction of sample handling time
- Oncology was
the largest and consumer genomics was the fastest-growing application
segment from 2018 to 2025
- Introduction
of targeted gene panels for cancerous cells is expected to drive demand
for efficient sample handling solutions in the coming years
- Illumina is
constantly working towards the development of next-generation sequencing
based in vitro diagnostic (IVD) solutions for cancer diagnostics.
- The company
has partnered with some of the leading biotechnology firms to develop
companion diagnostics targeting cancer
- For
instance, Illumina partnered with Loxo Oncology in April 2018 to develop
NGS-based pan-cancer companion diagnostic solutions for solid tumors
- Similarly,
continuous introduction of novel solutions for consumer genomics is
driving growth in the NGS sample preparation market
- Companies
such as 23andMe, Color Genomics, Helix, and Counsyl are active players in
the consumer genomics segment
- Clinical
research segment is projected to grow with the highest CAGR in the coming
years
- Rising
adoption of sequencing associated CLIA waived diagnostic tests among these
end-users is anticipated to boost growth
- Although
U.S. accounted for the largest share on the current market scenario,
potential opportunities offered by emerging nations is attributive to the
fastest growth rate of Asia Pacific region
- China and
India are expected to witness substantial penetration in the coming years
with respect to implementation of biotechnological advances
- Agilent
Technologies.; BGI; Biomatters Ltd.; Bio-Rad Laboratories, Inc.; Congenica
Ltd; DNASTAR; Eurofins Scientific; F. Hoffmann-La Roche Ltd; Foundation
Medicine; Genomatix GmbH; Illumina; Macrogen; Myriad Genetics; Oxford
Nanopore Technologies; Pacific Biosciences of California; Partek
Incorporated; Perkin Elmer; PierianDx; QIAGEN; Quest Diagnostics
Incorporated; and Thermo Fisher Scientific are the prominent participants operating
in this market
- These
companies are working towards the development of novel products and
workflows that can help ease the bottlenecks associated with the
integration of sequencing in clinical medicine
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment